How does Geert Vanden Bossche expect the SARS-COV2 virus to react to the mass vaccination programme?

Responsive Centered YouTube Video

Dr. Philip McMillan discusses Gert Vanden Bossche’s predictions on SARS-COV2 virus reaction to mass vaccination. • 0:01
No guarantee on accuracy of predictions, but considering all possibilities is crucial for risk management. • 0:21
Gert’s accurate predictions in the past raise concerns about potential worst outcomes. • 0:46
Gert warns about poor neutralizing capacity in vaccinated populations leading to spread of highly infectious variants. • 1:28
Emphasis on prospective analysis based on understanding virus-host interplay rather than standard modeling. • 3:05

Increasing immune pressure from mass vaccination favors more infectious variants. • 3:57
Higher vaccine coverage rates lead to dominance of more infectious variants. • 4:03
More infectious variants like Omicron may have an advantage due to immune pressure. • 4:34
Omicron increases infectiousness by evading neutralizing antibodies. • 4:59
Vaccinated individuals may have poor neutralizing capacity against Omicron. • 6:04
Diminished neutralizing capacity results in higher infection-enhancing antibodies. • 7:08

Omicron may have the advantage of spreading further due to non-neutralizing antibodies enhancing infection. • 7:26
Scientific community debates on the term ‘antibody dependent enhancement of infection’ in relation to Omicron. • 7:45
Omicron is perceived as less virulent and may lead to decreased shedding of the virus by vaccinated individuals. • 8:46
Increased infectiousness, decreased virulence, and shedding patterns are observed with Omicron. • 9:25
Resistance to neutralizing antibodies may inhibit trans infection and viral replication on dendritic cells. • 10:51

Paper discusses how lectins enhance SARS-CoV-2 infection in cells with low ACE2 levels. • 11:37
Virus can spread from cell to cell without using ACE2 in cells with low ACE2 levels. • 12:20
Neutralizing antibodies may increase infectiousness in upper respiratory tract. • 13:04
Antibodies predicted to promote cell-to-cell spread in lower respiratory tract, potentially increasing virulence. • 13:32
Poor neutralizing capacity could lead to super variants with high infectivity and virulence. • 14:35
Current phase shows high infectiousness but not high virulence, potential for change with viral evolution. • 15:02